We are live on ! Find out more
GRCE

Grace Therapeutics

13 hedge funds and large institutions have $190K invested in Grace Therapeutics in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

662% more capital invested

Capital invested by funds: $24.9K → $190K (+$165K)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

30% more funds holding

Funds holding: 1013 (+3)

0.13% more ownership

Funds ownership: 0.02%0.15% (+0.13%)

Holders
13
Holders Change
+3
Holders Change %
+30%
% of All Funds
0.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
1
Reduced
Closed
2
Calls
Puts
Net Calls
Net Calls Change

GRCE Hedge Fund Activity: Q1 2023 in Review

13 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q1 2023, worth a combined $190K — up 662% from $24.9K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GRCE positions and 2 closed out — a net gain of 3 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was TD Private Client Wealth, opening a new position worth an estimated $143K. The largest seller was Money Concepts Capital, exiting entirely with an estimated $94 sold.

  • 13 institutional investors held Grace Therapeutics (GRCE) as of Q1 2023, up from 10 in Q4 2022.
  • Funds reported $190K of Grace Therapeutics stock for Q1 2023, up 662% quarter-over-quarter.
  • 5 funds opened new Grace Therapeutics positions in Q1 2023 and 2 closed out, a net change of +3 holders.
  • The largest Grace Therapeutics buyer in Q1 2023 was TD Private Client Wealth, an estimated $143K added.
  • The largest Grace Therapeutics seller in Q1 2023 was Money Concepts Capital, an estimated $94 sold.

Based on aggregated 13F filings for Q1 2023.